Crosstalk between dendritic cells and regulatory T cells: Protective effect and therapeutic potential in multiple sclerosis
R Li, H Li, X Yang, H Hu, P Liu, H Liu - Frontiers in Immunology, 2022 - frontiersin.org
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system
related to autoimmunity and is characterized by demyelination, neuroinflammation, and …
related to autoimmunity and is characterized by demyelination, neuroinflammation, and …
[HTML][HTML] Protective effects of different Bacteroides vulgatus strains against lipopolysaccharide-induced acute intestinal injury, and their underlying functional genes
Abstract Introduction The roles of Bacteroides species in alleviating inflammation and
intestinal injury has been widely demonstrated, but few studies have focused on the roles of …
intestinal injury has been widely demonstrated, but few studies have focused on the roles of …
Oligodendrocyte-derived extracellular vesicles as antigen-specific therapy for autoimmune neuroinflammation in mice
Autoimmune diseases such as multiple sclerosis (MS) develop because of failed peripheral
immune tolerance for a specific self-antigen (Ag). Numerous approaches for Ag-specific …
immune tolerance for a specific self-antigen (Ag). Numerous approaches for Ag-specific …
Mdivi-1 modulates macrophage/microglial polarization in mice with EAE via the inhibition of the TLR2/4-GSK3β-NF-κB inflammatory signaling axis
X Liu, X Zhang, X Niu, P Zhang, Q Wang, X Xue… - Molecular …, 2022 - Springer
Macrophage/microglial modulation plays a critical role in the pathogenesis of multiple
sclerosis (MS), which is an inflammatory disorder of the central nervous system. Dynamin …
sclerosis (MS), which is an inflammatory disorder of the central nervous system. Dynamin …
Mdivi-1, a mitochondrial fission inhibitor, modulates T helper cells and suppresses the development of experimental autoimmune encephalomyelitis
YH Li, F Xu, R Thome, MF Guo, ML Sun… - Journal of …, 2019 - Springer
Abstract Background Unrestrained activation of Th1 and Th17 cells is associated with the
pathogenesis of multiple sclerosis and its animal model, experimental autoimmune …
pathogenesis of multiple sclerosis and its animal model, experimental autoimmune …
IL-27 Regulated CD4+IL-10+ T Cells in Experimental Sjögren Syndrome
J Qi, Z Zhang, X Tang, W Li, W Chen… - Frontiers in immunology, 2020 - frontiersin.org
Interleukin 27 (IL-27) plays diverse immune regulatory roles in autoimmune disorders and
promotes the generation of IL-10–producing CD4+ T cells characterized by producing the …
promotes the generation of IL-10–producing CD4+ T cells characterized by producing the …
IFN-β acts on monocytes to ameliorate CNS autoimmunity by inhibiting proinflammatory cross-talk between monocytes and Th cells
IFN-β has been the treatment for multiple sclerosis (MS) for almost three decades, but
understanding the mechanisms underlying its beneficial effects remains incomplete. We …
understanding the mechanisms underlying its beneficial effects remains incomplete. We …
CD40 agonist overcomes T cell exhaustion induced by chronic myeloid cell IL-27 production in a pancreatic cancer preclinical model
AL Burrack, MR Rollins, EJ Spartz… - The Journal of …, 2021 - journals.aai.org
Pancreatic cancer is a particularly lethal malignancy that resists immunotherapy. In this
study, using a preclinical pancreatic cancer murine model, we demonstrate a progressive …
study, using a preclinical pancreatic cancer murine model, we demonstrate a progressive …
Dual peptide nanoparticle platform for enhanced antigen-specific immune tolerance for the treatment of experimental autoimmune encephalomyelitis
H Wang, J Shang, Z He, M Zheng, H Jia, Y Zhang… - Biomaterials …, 2022 - pubs.rsc.org
Current therapeutic strategies for autoimmune diseases such as multiple sclerosis (MS) are
directed towards nonspecific immunosuppression, which has severe side effects. The …
directed towards nonspecific immunosuppression, which has severe side effects. The …
[HTML][HTML] IL-6–targeted therapies to block the cytokine or its receptor drive distinct alterations in T cell function
C Speake, T Habib, K Lambert, C Hundhausen… - JCI insight, 2022 - ncbi.nlm.nih.gov
Therapeutics that inhibit IL-6 at different points in its signaling pathway are in clinical use, yet
whether the immunological effects of these interventions differ based on their molecular …
whether the immunological effects of these interventions differ based on their molecular …